文献速递神经肿瘤

胶质瘤与脑转移瘤术前及术后早期血清GFAP水平

Pre- and early postoperative GFAP serum levels in glioma and brain metastases.
PubMed 文献 · J Neurooncol · 2018-05-24

前瞻性研究纳入2009年9月至2010年8月32例患者(胶质瘤25例、脑转移瘤7例),用Elecsys GFAP原型试验检测围手术期血清GFAP。术前胶质瘤组血清GFAP显著高于脑转移瘤组(0.18 vs 0.08 µg/l,p=0.0198),术后各时间点两组无显著差异;术后胶质瘤肿瘤体积与血清GFAP无显著相关。作者认为sGFAP似乎不适合在急性术后阶段检测残留胶质瘤组织。

要点

  • 术前胶质瘤组sGFAP为0.18 µg/l,脑转移瘤组为0.08 µg/l,差异显著(p=0.0198)。
  • 术后sGFAP升高,术后第1天达峰值,至术后第7天未恢复至术前水平。
  • 术后各时间点胶质瘤与脑转移瘤组间sGFAP均无显著差异。

核心结论

  • 根据本研究数据,血清GFAP似乎不适合在急性术后阶段检测残留胶质瘤组织。

研究设计与样本

  • 前瞻性研究,2009年9月至2010年8月前瞻性招募32例患者,其中胶质瘤25例、脑转移瘤7例。
  • 使用ElecsysR GFAP原型试验(Roche Diagnostics,Penzberg/Germany)以电化学发光免疫分析法检测血清GFAP。
  • 检测术前及术后早期至出院前不同时间点的血清GFAP水平。

主要发现

  • 术前血清GFAP胶质瘤组为0.18 µg/l,脑转移瘤组为0.08 µg/l,两组差异显著(p=0.0198,Welch t检验)。
  • 术后血清GFAP升高,但胶质瘤与脑转移瘤患者在其他任何时间点均无显著差异。
  • 血清GFAP峰值出现在术后第1天,随后轻度下降,至术后第7天未恢复至术前水平。
  • 单变量分析中,术后胶质瘤肿瘤体积与血清GFAP水平无显著相关性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SUBJECT: To date there is no established tumor marker for the clinical follow-up of glioblastoma, WHO grade IV, (GBM) which constitutes the most frequent and malignant primary brain tumor. However, since there is promising data that the serum glial fibrillary acidic protein (sGFAP) may serve as a biomarker for glial brain tumors, this prospective study aimed at evaluating the diagnostic relevance of perioperative changes in sGFAP levels for the assessment of residual glial tumor tissue in patients undergoing surgery of intracerebral tumors. METHODS: Serum GFAP was measured using an electrochemiluminometric immunoassay (ElecsysR GFAP prototype test, Roche Diagnostics, Penzberg/Germany) in 32 prospectively recruited patients between September 2009 and August 2010. Twenty-five were diagnosed with glioma and seven with brain metastases (BM). We assessed sGFAP levels prior to and at different time points during the early postoperative phase until patient discharge. RESULTS: There were only significant differences in the pre-operative sGFAP levels of patients with gliomas compared to BM (0.18 vs. 0.08 µg/l; p = 0.0198, Welch's t-Test). Even though there was an increase of sGFAP after surgery, there were no significant differences between glioma and BM patients at any other time point. Peak sGFAP levels where reached on postoperative day 1 followed by a slight decrease, but not reaching pre-operative levels until postop day 7. There was no significant correlation between postoperative glioma tumor volume and sGFAP levels in univariate analyses. CONCLUSION: According to our data sGFAP does not appear to be suitable to detect residual glioma tissue in the acute postoperative phase.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Baumgarten P, Quick-Weller J, Gessler F, et al. Pre- and early postoperative GFAP serum levels in glioma and brain metastases. J Neurooncol. 2018. PMID: 29797180. doi:10.1007/s11060-018-2898-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。